|
| Reference | Patient cohort | Method of detection | Reported result | Comment |
|
| Hauptman et al. (1974) | 18 patients with Laennec’s cirrhosis and history of alcoholic abuse | Affinity purification of cirrhotic sera by adsorption over albumin-loaded column followed immunoelectrophoresis and immunoblot | 7 out of 18 patients had detectable IgA antibodies against albumin | Pts. with antialbumin antibodies showed marked hypoalbuminemia and hypergammaglobulinemia |
|
| Hellstrom et al. (1989) | 8 patients with hepatitis B (all HbsAgpos, 4 pts. anti-HBepos/HBV-DNAneg) | Ex vivo stimulation of isolated B-cells; supernatants were then assayed by ELISA | In all patients, antialbumin IgG was found in the supernatant | |
|
| Louzir et al. (1992) | 56 patients with HBV-related liver disease (50 pts HBsAg pos, 6 HBsAgneg, and anti-Hbcpos) | Patients’ sera were measured by ELISA | In 69.3, 64.5, and 24.2% of the pts, antialbumin antibodies of the IgG, IgA, or IgM class were detected | |
|
| Lenkei et al. (1980) | 275 hepatic patients (“mostly with acute hepatitis”) | Sera were tested by antialbumin (AA) agglutination | 51 HbsAgneg pts. with high AA-agglutination titre | Antigen: polymerized albumin |
|
| Lindstrom et al. (1978) | 19 pts, nine pts with prolonged nitrofurantoin therapy and tailing albumin phenomenon (TA), control sera from ten patients without TA | Sera were tested by ELISA | Patients with TA phenomenon showed higher IgG antialbumin levels (measured as absorbance) compared to patients without TA | Follow-up of one patient with TA and nitrofurantoin available: IgG antialbumin levels decreased after cessation of nitrofurantoin |
|
| Onica et al. (1983) | 8 healthy individuals, 25 patients with various liver disease (14 pts acute viral hepatitis, 8 pts chronic hepatitis, and 3 pts liver cirrhosis) | Affinity purification of sera by adsorption over albumin-loaded column followed radioimmunoassay and immunodiffusion | 3 healthy individuals showed antialbumin antibodies (IgG/IgM/no IgA); 10 patients harbored antialbumin antibodies (IgG/IgM/no IgA) | Antigen: polymerized albumin |
|
| Tamura et al. (1982) | 54 healthy controls, 77 patients with liver disease (8 acute hepatitis, 15 chronic persistent hepatitis, 14 chronic active hepatitis without liver cirrhosis (LC), 16 alcoholic LC, 9 nonalcoholic LC, and 15 hepatocellular carcinoma) | Antibodies in sera or protein fractions were detected with microhaemagglutination assay | Antibodies to human albumin were found in 22% of the patients, antibodies to bovine serum albumin in 48% of the patients | |
|
| Brown et al. (1985) | Four groups; group I: 19 healthy individuals who never received immunotherapy or exogenous albumin. Group II: 8 individuals who had received exogenous albumin in the past but no immunotherapy; group III: 26 patients who had received immunotherapy not containing albumin and no exogenous albumin
Group IV: 215 patients who had received immunotherapy containing albumin | Antibodies were detected in sera by ELISA | Individuals exposed to albumin did not harbor increased antialbumin titres compared to individuals who were never exposed to albumin | |
|
| Bosse et al. (2005) | 500 healthy individuals received repeated intramuscular injections in weekly intervals; 30 healthy subjects received intravenous albumin infusions | Antialbumin antibodies were assayed by ELISA from sera | Treatment did not change or increase antibody titres | Double-blind, randomized trial |
|
| Mangili et al. (1988) | 29 patients with diabetes type 1; 20 healthy individuals | Antialbumin antibodies were assayed by ELISA from sera | Antibodies (IgG/IgM) against modified (glucitol-albumin, ketoamin-albumin) and unmodified albumin were found in both diabetic and healthy individuals; higher titres were more common in diabetic patients | |
|
| Raghav et al. (2017) | 50 patients with type 1 diabetes, 50 patients with type 2 diabetes, 50 patients with gestational diabetes, 50 patients with type 2 diabetes and chronic kidney disease, and 50 healthy controls | Antialbumin antibodies were assayed by ELISA from sera | Patients with type 1 and type 2 diabetes showed increased levels of antibodies directed against glycated albumin | |
|
